187 related articles for article (PubMed ID: 22024742)
1. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
[TBL] [Abstract][Full Text] [Related]
2. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
3. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
4. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
[TBL] [Abstract][Full Text] [Related]
5. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
Angelova AL; Aprahamian M; Grekova SP; Hajri A; Leuchs B; Giese NA; Dinsart C; Herrmann A; Balboni G; Rommelaere J; Raykov Z
Clin Cancer Res; 2009 Jan; 15(2):511-9. PubMed ID: 19147756
[TBL] [Abstract][Full Text] [Related]
6. Oncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement.
Réjiba S; Bigand C; Parmentier C; Masmoudi A; Hajri A
PLoS One; 2013; 8(8):e70594. PubMed ID: 23967078
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
8. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
[TBL] [Abstract][Full Text] [Related]
9. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Hajda J; Leuchs B; Angelova AL; Frehtman V; Rommelaere J; Mertens M; Pilz M; Kieser M; Krebs O; Dahm M; Huber B; Engeland CE; Mavratzas A; Hohmann N; Schreiber J; Jäger D; Halama N; Sedlaczek O; Gaida MM; Daniel V; Springfeld C; Ungerechts G
Clin Cancer Res; 2021 Oct; 27(20):5546-5556. PubMed ID: 34426438
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
Bhat R; Dempe S; Dinsart C; Rommelaere J
Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
[TBL] [Abstract][Full Text] [Related]
12. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
13. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
14. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
Viruses; 2021 May; 13(6):. PubMed ID: 34071585
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
17. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
18. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A
EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664
[TBL] [Abstract][Full Text] [Related]
19. Regression of glioma in rat models by intranasal application of parvovirus h-1.
Kiprianova I; Thomas N; Ayache A; Fischer M; Leuchs B; Klein M; Rommelaere J; Schlehofer JR
Clin Cancer Res; 2011 Aug; 17(16):5333-42. PubMed ID: 21715567
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
